Rua launches our first medicine in New Zealand
Rua Bioscience, has today launched our first medicine, marking a significant milestone for New Zealand patients, prescribers and the medicinal cannabis industry.
Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent
Rua Half-Year Result – Constructive Period with First Product, First Revenue Imminent. Rua Bioscience Limited (NZX: RUA) has today announced its financial results for the six months to 31 December 2021.
The loss after tax for the six months to 31 December 2021 was $2.46m, with total cash and investments on hand at the end of the period of $12.29m.